Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer

Table 1

Cox proportional hazards analysis for progression-free survival in stage IIIA-N2 NSCLC patients.

		Sx	Wald	OR (95% CI)
Gender (male, female)	0.31966	0.388585	0.822626	1.4 (0.64-2.9)	0.417
Age, yr (≤60, >60)	-0.37059	0.496416	-0.74654	0.69 (0.26-1.8)	0.438
Smoking (Y, N)	-0.83781	0.394112	-2.12581	0.43 (0.2-0.94)	0.031
KPS (>80, ≤80)	-0.24517	0.388775	-0.63062	0.78 (0.37-1.7)	0.527
Largest tumor diameter (<3, 3-4.9, and ≥5)	-0.02777	0.28055	-0.099	0.97 (0.56-1.7)	0.921
Histology (adenocarcinoma, nonadenocarcinoma)	0.15502	0.470391	0.329556	1.2 (0.46-2.9)	0.738
pT status (T1-2, T3)	-0.23663	0.543001	-0.43579	0.79 (0.27-2.3)	0.654
cN2 (Y, N)	0.356603	0.380638	0.937093	1.4 (0.68-3)	0.350
Tumor differentiation (well differentiated, poorly differentiated)	-0.57978	0.484415	-1.19686	0.56 (0.22-1.4)	0.253
Met mutation (Y, N)	0.431686	0.507633	0.850389	1.5 (0.57-4.2)	0.415
Mutation	-0.88498	0.397069	-2.22878	0.41 (0.19-0.9)	0.028
Mutation	-0.78888	0.407384	-1.93645	0.45 (0.2-1)	0.045